<DOC>
	<DOCNO>NCT00865280</DOCNO>
	<brief_summary>A Phase III trial demonstrate safety efficacy PTK 0796 treatment complicate skin skin structure infection ( cSSSI ) .</brief_summary>
	<brief_title>Study Safety Efficacy PTK 0796 Patients With Complicated Skin Skin Structure Infection ( CSSSI )</brief_title>
	<detailed_description>The pharmacologic profile PTK 0796 human suggest potential use safely effectively indication . Data vitro animal study support hypothesis . In PTK 0796-CSSI-0804 safety efficacy PTK 0796 treatment cSSSI compare antibiotic approve indication FDA . Initial treatment administer intravenously option subsequent oral treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>Patients , age 18 year old Is expect require â‰¥4 day IV antibiotic therapy Has acute complicate skin skin structure infection finding systemic inflammatory response Female patient must pregnant time enrollment must agree reliable method birth control study 30 day follow last dose study drug Has receive investigational drug within past 1 month Has previously enrol protocol Has receive &gt; 24 hr potentially effective systemic antibiotic immediately prior study drug Is nurse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>CSSI</keyword>
	<keyword>Abscess</keyword>
	<keyword>Wound</keyword>
	<keyword>Cellulitis</keyword>
	<keyword>Complicated Skin Skin Structure Infections ( cSSSI )</keyword>
</DOC>